![](img/space.gif) |
Az alpha2-plazmin inhibitor természetes heterogenitásának szerepe a trombotikus megbetegedésekben
|
súgó
nyomtatás
|
Ezen az oldalon az NKFI Elektronikus Pályázatkezelő Rendszerében nyilvánosságra hozott projektjeit tekintheti meg.
vissza »![](img/space.gif)
![](img/space.gif)
![](img/space.gif)
![](img/space.gif)
|
![](img/print_ver.gif) |
Közleményjegyzék |
|
|
Zsuzsanna Bagoly, Barbara Baráth, Rita Orbán-Kálmándi, István Szegedi, Réka Bogáti, Ferenc Sarkady, László Csiba, Éva Katona: Incorporation of alpha2-Plasmin Inhibitor into Fibrin Clots and Its Association with the Clinical Outcome of Acute Ischemic Stroke Patients, BIOMOLECULES, 11, 347. https://doi.org/10.3390/biom11030347, 2021 | Barbara Baráth: Effect of α2-plasmin inhibitor heterogeneity on the risk of venous thromboembolism, Thrombosis Research 203: 110–116, 2021 | Baráth Barbara: Az α2-plazmin inhibitor szerepének vizsgálata trombotikus megbetegedésekben , https://dea.lib.unideb.hu/dea/bitstream/handle/2437/321320/Barath_Barbara_ertekezes_titkositott.pdf?sequence=1&isAllowed=y, 2021 | Barbara Baráth, Rita Orbán-Kálmándi, Zsuzsa Bagoly, Éva Katona: Effect of alpha2-plasmin inhibitor C-terminal forms on in vitro clot lysis, ISTH virtual congress July 17-21, 2021. https://abstracts.isth.org/meetings/isth-2021-congress/?alpha=e, 2021 | Barbara Baráth, Rita Orbán-Kálmándi, Zsuzsa Bagoly, Éva Katona: Investigation of alpha2-plasmin inhibitor C-terminal heterogeneity in normal human plasma samples and its effect on in vitro clot lysis time, MLDT 60 Virtual Congress, 2021 | Katona É, Muszbek L.: The laboratory diagnosis of inherited FXIII deficiencies and the measurement of FXIII activity and antigen level, ECAT Foundation, Special Issue 7: 22-26, 2018 | Muszbek L, Katona É, Pénzes K: Antibodies against factor XIII subunits, ECAT Foundation, Special Issue 7: 17-21, 2018 | Barbara Baráth, Rita Orbán-Kálmándi, Zsuzsa Bagoly, Éva Katona: Effect of alpha2-plasmin inhibitor C-terminal forms on in vitro clot lysis, ISTH virtual congress July 17-21, 2021. https://abstracts.isth.org/meetings/isth-2021-congress/?alpha=e, 2021 | Barbara Baráth, Rita Orbán-Kálmándi, Zsuzsa Bagoly, Éva Katona: Investigation of alpha2-plasmin inhibitor C-terminal heterogeneity in normal human plasma samples and its effect on in vitro clot lysis time, MLDT 60 Virtual Congress, 2021 | Mezei ZA, Katona É, Kállai J, Bereczky Z, Somodi L, Molnár É, Kovács B, Miklós T, Ajzner É, Muszbek L: Factor XIII levels and factor XIII B subunit polymorphisms in patients with venous thromboembolism, THROMB RES 158: 93-97, 2017 | Mezei ZA, Katona É, Kállai J, Bereczky Z, Somodi L, Molnár É, Kovács B, Miklós T, Ajzner É, Muszbek L: Factor XIII levels and factor XIII B subunit polymorphisms in patients with venous thromboembolism, THROMB RES 158: 93-97, 2017 | Éva Katona, Réka Bogáti, Tünde Miklós, Réka Gindele, Marianna Speker, Viktória Fedoriska, Adrienn Teráz-Orosz, Zoltán Mezei, Zsuzsanna Bereczky: The effect of alpha-2 plasmin inhibitor activity and antigen levels and p.Arg6Trp polymorphism on the risk of venous thromboembolism, 64th Annual Meeting of the ISTH SSC, July 18-21 2018, Dublin, 2018 | Barbara Baráth, Zsuzsa Bagoly, István Szegedi, Rita Kálmándi, László Csiba, Éva Katona: Incorporation of α2-plasmin inhibitor into fibrin clots and its association with the clinical outcome of acute ischemic stroke patients receiving thrombolytic therapy, 25th Biennial International Congress on Thrombosis, 2018. 05. 23-27., Venice, Italy, 2018 | Baráth Barbara, Bogáti Réka, Miklós Tünde, Gindele Réka, Speker Marianna, Fedoriska Viktória, Teráz-Orosz Adrienn, Mezei Zoltán, Bereczky Zsuzsanna, Katona Éva: 1. Alpha-2 plazmin inhibítor aktivitás, antigén szintek és p.Arg6Trp polimorfizmus vénás tromboembólián átesett betegekben, MTHT XIV. Kongresszusa, 2018. szeptember 27-29, Mátraháza, 2018 | Katona É, Baráth B, Szegedi I, Kálmándi R, Csiba L, Bagoly Z: 2. Az α2-plazmin inhibitor beépülése a fibrin alvadékba és kapcsolata a trombolízis kimenetelével akut iszkémiás stroke-on átesett betegekben, MTHT XIV. Kongresszusa, 2018. szeptember 27-29, Mátraháza, 2018 | Muszbek L, Pénzes K, Katona É: Auto- and alloantibodies against factor XIII: laboratory diagnosis and clinical consequences, Journal of Thrombosis and Haemostasis 16: 822-832, 2018 | Katona É, Muszbek L.: The laboratory diagnosis of inherited FXIII deficiencies and the measurement of FXIII activity and antigen level, ECAT Foundation, Special Issue 7: 22-26, 2018 | Muszbek L, Katona É, Pénzes K: Antibodies against factor XIII subunits, ECAT Foundation, Special Issue 7: 17-21, 2018 | Muszbek L, Pénzes K, Katona É: Auto- and alloantibodies against factor XIII: laboratory diagnosis and clinical consequences, Journal of Thrombosis and Haemostasis 16: 822-832, 2018 | Teráz-Orosz A, Csapó A, Bagoly Z, Székely EG, Tóth E, Kovács B, Bereczky Z, Muszbek L, Katona É: A new ELISA method for the measurement of total alpha(2)-plasmin inhibitor level in human body fluids, JOURNAL OF IMMUNOLOGICAL METHODS, 471:27-33., 2019 | Bryk AH, Siudut J, Broniatowska E, Bagoly Z, Baráth B, Katona É, Undas A: Sex-specific alteration to α2-antiplasmin incorporation in patients with type 2 diabetes, Thrombosis Research, DOI: 10.1016/j.thromres.2019.09.032, 2019 | Éva Katona, Barbara Baráth, Réka Bogáti, Tünde Miklós, Dóra Pituk, Viktória Fedoriska, Adrienn Teráz-Orosz, László Muszbek, Zsuzsanna Bereczky: Alpha2-plasmin inhibitor and its C-terminal proteolytic variation in venous thrombosis, ECTH 2019 (European Congress on Thrombosis and Haemostasis), Oct 2-5, Glasgow, 2019 | Barbara Baráth, Réka Bogáti, Tünde Miklós, Viktória Fedoriska, Dóra Pituk, Adrienn Teráz-Orosz, Zoltán Mezei, Zsuzsanna Bereczky, Éva Katona: Soluble fibroblast activation protein (sFAP) and alpha2-plasmin inhibitor p.Arg6Trp polymorphism in venous thrombosis, ECTH 2019 (European Congress on Thrombosis and Haemostasis), Oct 2-5, Glasgow, 2019 | Teráz-Orosz A, Csapó A, Bagoly Z, Székely EG, Tóth E, Kovács B, Bereczky Z, Muszbek L, Katona É: A new ELISA method for the measurement of total alpha(2)-plasmin inhibitor level in human body fluids, JOURNAL OF IMMUNOLOGICAL METHODS, 471:27-33., 2019 | Bryk AH, Siudut J, Broniatowska E, Bagoly Z, Baráth B, Katona É, Undas A: Sex-specific alteration to α2-antiplasmin incorporation in patients with type 2 diabetes, Thrombosis Research, DOI: 10.1016/j.thromres.2019.09.032, 2019 | Bovet Julien, Hurják Boglárka, De Maistre Emmanuel, Katona Éva, Pénzes Krisztina, Muszbek László: Autoimmune factor XIII deficiency with unusual laboratory and clinical phenotype, JOURNAL OF THROMBOSIS AND HAEMOSTASIS 18: (6) pp. 1330-1334., 2020 | Plamenova I, Zolkova J, Sokol J, Kolkova Z, Bereczky Zs, Katona É, Muszbek L, Kubisz P, Stasko J: Genetic background of inherited factor XIII-A subunit deficiency: Review of the literature and description of two new cases, Semin Thromb Hemost, DOI https://doi.org/ 10.1055/s-0041-1725170, 2021 | Zabczyk M, Natorska J, Bagoly Z, Sarkady F, Barath B, Katona E, Bryk A, Zettl K, Wisniewski J R, Undas A: Plasma fibrin clots of pulmonary embolism patients present increased amounts of factor XIII and alpha2-antiplasmin at 3 months' anticoagulation since the acute phase., JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY 71: (4) p. 1., 2020 | Plamenova I, Zolkova J, Sokol J, Kolkova Z, Bereczky Z, Katona É, Muszbek L, Kubisz P, Stasko J: Genetic background of inherited factor XIII-A subunit deficiency: Review of the literature and description of two new cases, Semin Thromb Hemost 47(7):885-889., 2021 |
![](img/space.gif)
|
|
|
![](img/shadow_right_up.gif)
|
![](img/shadow_left_bottom.gif)
|
![](img/shadow_right_bottom.gif)
|
![](img/space.gif)
vissza »
|
![](img/space.gif) |
|